• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
  LongeCity
              Advocacy & Research for Unlimited Lifespans

Photo

Current State of Longevity Clinical Trials

longevity clinical trials

  • Please log in to reply
No replies to this topic

#1 Engadin

  • Guest
  • 198 posts
  • 580
  • Location:Madrid
  • NO

Posted 18 September 2019 - 08:45 PM


.

 

 

 

 

S O U R C E :    LinkedIn

 

 

 

 

Longevity drug development has evolved from a distant goal into an industry priority. A number of companies are working on developing drugs that target aging and some of these drugs are currently in clinical trials. This article is an overview of the current state of Longevity clinical trials. Although no Longevity drugs have received regulatory approval yet, a number of Longevity therapies have passed phase I and phase II clinical (human) trials, and a few are in phase III trials. In this article we review the progression of clinical trials and look at which hallmarks of aging are receiving the most pharmacological attention.

 

 

Aging is the biggest risk factor for developing many diseases including Alzheimer’s, osteoporosis, cardiovascular disease, and cancer. Drugs that target aging will reduce suffering and benefit humanity.

 

 

AAA.png

 

 

Companies working in Longevity drug development are more advanced than traditional biomedicine companies. Longevity companies are considered next generation because Longevity research and development integrates many scientific and technical subdomains including AI, digital medicine, and geroscience. Longevity companies also use very advanced methods of diagnostic and prognostic assessment and next generation techniques for conducting clinical trials compared to conventional standards which are largely based on results from in vitro experiments and model organisms (mice).

 

 

Developing drugs for healthy Longevity is one of the most complex areas in drug discovery. Longevity focuses on prevention rather than treatment and requires complete optimization of health at the deepest level targeting biological systems that control disease.

 

 

In the Longevity industry there are nine hallmarks of aging which are considered to be the root causes of aging. We have categorized Longevity drugs by which hallmark they target. Our categorization is based on the Hallmarks of Aging, published in Cell in 2013This paper is highly regarded in academia and is one of the most cited papers in biology averaging one citation every two days. The paper divides aging into nine distinct categories. Each category is a hallmark of aging damage used to explain how the aging process works and how it causes age-related diseases. Discoveries in each category have led to clinical trials. Each clinical trial is a step closer to ameliorating these hallmarks. A detailed breakdown of each category can be found at LifeSpan.io.

 

 

Nine categories of Longevity Drugs
 
 
  1. Genomic instability
  2. Telomere attrition
  3. Epigenetic alterations
  4. Loss of proteostasis
  5. Deregulated nutrient-sensing
  6. Mitochondrial dysfunction
  7. Cellular senescence
  8. Stem cell exhaustion
  9. Altered intercellular communication

 

 

 

.../...

 

 

CONTINUED AT SOURCE

 

 

.


  • Informative x 1




1 user(s) are reading this topic

0 members, 1 guests, 0 anonymous users